Deerfield Management Company, L.P. (Series C) Catalyst Pharmaceuticals, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $3.95 Billion
- Q1 2025
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,422,149 shares of CPRX stock, worth $81 Million. This represents 2.1% of its overall portfolio holdings.
Number of Shares
3,422,149
Previous 3,133,011
9.23%
Holding current value
$81 Million
Previous $65.4 Million
26.92%
% of portfolio
2.1%
Previous 1.62%
Shares
10 transactions
Others Institutions Holding CPRX
# of Institutions
389Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$443 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$201 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$131 Million0.01% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$74.2 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.96MShares$70 Million0.12% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.43B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...